<DOC>
	<DOC>NCT01597999</DOC>
	<brief_summary>This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.</brief_summary>
	<brief_title>Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer</brief_title>
	<detailed_description>Dedicated Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients with invasive ductal carcinoma Patients undergoing DCEMRI scan which are assessed according to BIRADS lexicon Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER2) response Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. Patients under 18 years old or during pregnancy Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>